**November 8, 2023** 

# Cost Pressures Weigh on Best Q3 Topline

Summary: In the 9M:2023 financial report, BUA Cement Plc. (BUACEMENT) recorded a remarkable +27.90%YoY revenue growth reaching NGN335.86bn, (vs NGN262.59bn in 9M:2022). The growth in revenue can be attributed to both price adjustments and increased sales volumes during the period. Notably, in Q3:2023, the company's revenue surged by 55.05%YoY to NGN114.79bn, marking the highest third-quarter growth on record (since Q3:2019), despite facing challenges like reduced export volumes due to the political situation in Niger which started in July. BUACEMENT reported significant surge in its cost of sales (+30.53%YoY), to NGN186.44bn. This was driven by higher energy costs (+26.67%YoY), material costs (+47.35%YoY), and operations & technical expenses (+58.34%YoY). Consequently, the Cost-to-sales ratio climbed to 55.54% (vs. 54.39% in 9M:2022). Additionally, operating expenses witnessed a substantial uptick (+48.39% YoY to NGN30.86bn), primarily due to increased distribution (+75.37%) and staff costs (+52.91%). In the same vein, finance costs jumped significantly by 269.19%YoY, owing to the substantial FX loss incurred (63.78% of finance cost) and the NGN139.89bn IFC syndicated 10-year loan (obtained at SOFR+5.5%). However, BUACEMENT reported lower effective tax rate for the period (11.29% vs 16.66% in 9M:2022), due to the firm's tax incentive. Thus, the firm's PAT grew marginally by 2.77% YoY to NGN76.07bn (from 74.01bn in 9M:2022).


**Positives**: Liquidity ratios improved to 1.13x, 0.84x and 0.60x (from 0.77x, 0.56x and 0.25x in 2022Y) due to increase in inventories (+43.52%), receivables (+768.41%) which offset the impact of the +1862%Ytd increase in dues to related parties.

**Negatives**: Gross and EBITDA margins declined to 44.49% and 35.63% (vs 45.61% and 37.79% in 9M:2022) owing to the growth in costs. Similarly, Net margin and interest coverage ratio declined to 22.65% and 2.51x (vs 28.19% and 7.19x in 9M:2022), due to the increase in interest expense on borrowings. Additionally, the firm's leverage remained high as its Debt-to-Total asset, Debt-to-EBIT and Debt to equity ratios grew to 0.37x, 3.16x and 0.96x, (vs 0.28x, 1.87x and 0.59x in 2022FY) respectively.

Our outlook for the 2023FY remains optimistic, driven by anticipated revenue growth (expected volumes growth from Q4 "win with the King promo" sales and dry season effect). Nevertheless, we acknowledge the ongoing influence of FX losses and inflation on operating expenses, as well as the impact of tax incentives on this outlook. With these factors in mind, we project a 12.04% YoY improvement in topline performance and

a 2.05% YoY increase in net profit. Valuation Trailing EPS 3.01 **BVPS** 25.81 P/E 35.17x P/BV 4.10x Target EV/EBITDA 16.48x Dec-2023 Exp. EBITDA per Share 4.87 Dec 2023 Target price NGN82.11 **Current Price** NGN105.00

Stock Highlights	
Yr Hi	105.80
Yr Lo	83.15
YTD return	+8.24%
Beta	0.41
Adjusted Beta	0.61
Shares outstanding	33.86bn
Market cap (NGN)	33.86trn
Financial year end	December
Most Recent Period	9M:2023



Sensitivity Analysis of Dec-2023 Target Price to Key Model Inputs					Min	71.49		
							Max	93.22
		4.56	4.62	4.87	5.12	5.37		
	16.36	71.49	75.58	79.67	83.76	87.85		
Target	16.61	72.59	76.74	80.89	85.04	89.20		
EV/EBITDA	16.86	73.68	77.89	82.11	86.32	90.54		
	17.11	74.77	79.05	83.33	87.60	91.88		
	17.36	75.86	80.20	84.54	88.88	93.22		

Recommendation: **SELL** TP: **82.11** CP: **105.0** UPP: **-21.80%** 

9M:2023	9M:2022	Y/Y Growth
335.86	262.59	27.90%
-186.44	-142.83	30.53%
149.42	119.77	24.76%
30.86	20.79	48.43%
1.12	0.27	310.77%
119.68	99.25	20.59%
85.75	89.33	-4.00%
76.07	74.01	2.77%
9M:2023	2022A	YtD Growth
707.15	669.01	5.70%
378.47	243.15	55.65%
1,016.91	874.01	16.35%
393.77	411.11	95.78%
359.17	205.34	74.92%
624.55	462.90	34.92%
	335.86 -186.44 149.42 30.86 1.12 119.68 85.75 76.07 9M:2023  707.15 378.47 1,016.91 393.77 359.17	335.86 262.59 -186.44 -142.83 149.42 119.77 30.86 20.79 1.12 0.27 119.68 99.25 85.75 89.33 76.07 74.01  9M:2023 2022A  707.15 669.01 378.47 243.15 1,016.91 874.01 393.77 411.11 359.17 205.34

### **Key Metrics**

110, 111001100			
Profitability Ratio	9M:2023	2022A	3-yr Hist. Avg
Return on Asset	25.46%	7.02%	11.50%
Return on Equity	19.32%	23.97%	21.52%
Net Margin	22.65%	27.98%	32.29%
Liquidity Ratio	9M:2023	2022A	3-yr Hist. Avg
Current Ratio	1.13x	0.77	0.97x
Quick Ratio	0.84x	0.56	0.76x
Efficiency Ratio	9M:2023	2022A	3-yr Hist. Avg
Asset Turnover	0.33x	0.41x	0.35x
Solvency Ratio	9M:2023	2022A	3-yr Hist. Avg
Debt-to-Asset Ratio	0.37x	0.28x	0.61x
Debt-to-Equity Ratio	0.96x	0.59x	0.30x

\*TP=Target Price, CP= Current Price, UPP=Upside Potential, EPS= Earnings Per Share, BVPS= Book Value Per Share, P/E=Price to Earnings, P/BV= Price to Book Value, T= Trailing, A= Actuals

## **DISCLAIMER**

### **Analysts' Certification and Disclaimer**

This research report has been prepared by the research analyst(s), whose name(s) appear(s) on the cover of this report. Each research analyst hereby certifies, with respect to each security or issuer covers in this research that:

- (1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or issuers (the Issuer); and
- (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. Research analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Meristem Securities Limited (the Firm). Like all of the Firm's employees, research analysts receive compensation that is impacted by overall Firm profitability, which includes revenues from other business units within the Firm.
- (3) each research analyst and/or persons connected with any research analyst may have interacted with sales and trading personnel, or similar, for the purpose of gathering, synthesizing and interpreting non-material non-public or material public market information.

As at the date of this report, any ratings, forecasts, estimates, opinions or views herein constitute a judgment, and are not connected to research analysts' compensations. In the case of non-currency of the date of this report, the views and contents may not reflect the research analysts' current thinking. This document has been produced independently of the Issuer. While all reasonable care has been taken to ensure that the facts stated herein are accurate and that the ratings, forecasts, estimates, opinions and views contained herein are fair and reasonable, neither the research analysts, the Issuer, nor any of its directors, officers or employees, shall be in any way responsible for the contents hereof, and no reliance should be placed on the accuracy, fairness or completeness of the information contained in this document. No person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith.

#### **Analysts' Compensation**

The equity research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Investment Banking.

### **Investment Ratings**

#### **Fair Value Estimate**

We estimate stock's fair value by computing a weighted average of projected prices derived from discounted cash flow and relative valuation methodologies. The choice of relative valuation methodology (ies) usually depends on the firm's peculiar business model and what in the opinion of our analyst is considered as a key driver of the stock's value from a firm specific as well as an industry perspective. However, we attach the most weight to discounted cash flow valuation methodology.

#### **Target Price Estimate**

While we believe that the fair value is underpinned by the future benefits stream and growth outlooks, which are primary drivers of value, the market might not align to the fair value estimate within the estimated investment horizon. Thus, we do not derive our target price from the fair value but from a trading perspective using the year projected earnings or book value and the respective target multiples. Notwithstanding, we are of the opinion that the variance between the two should not be too significant.

### **Ratings Specification**

**BUY**: Target Price of the stock is above the current market price by at least 10 percent

**HOLD**: Target Price of the stock ranges between -10 percent and 10 percent from the current market price.

**SELL**: Target Price of the stock is more than 10 percent below the current market price.

### **Movements in Price Target**

Company Name: BUA Cement Plc

		Previous Target	New Target	Previous	New
Date	Price (N)	Price(N)	Price (N)	Recommendation	Recommendation
8-Nov -2023	105.00	82.11	-	SELL	SELL
21-July-2023	95.00	73.82	82.11	SELL	SELL

### **Company disclosures**

Meristem or the analyst(s) responsible for the coverage may have financial or beneficial interest in securities or related investments discussed in this report, which could, unintentionally, affect the objectivity of this report. Material interests, which Meristem or the analyst(s) have with companies or in securities discussed in this report, are disclosed below:

Company	Disclosure
BUA Cement Plc	

- a. The analyst(s) hold(s) personal positions (directly or indirectly) in a class of the common equity securities of the company.
- b. The analyst responsible for this report, as indicated on the front page, is a board member, officer, or director of the company
- c. Meristem beneficially owns 1% or more of the equity securities of the company
- d. Meristem has been the lead manager or co-lead manager of any publicly disclosed offer of securities of the company over the past 12 months.
- e. Meristem beneficially holds a major interest in the debt of the company
- f. Meristem has received compensation for investment banking activities from the company within the last 12 months
- g. Meristem intends to seek or anticipates receipt of compensation for investment banking services from the company in the next 3 months
- h. The content of this research report has been communicated with the company, following which this research has been materially amended before its distribution
- i. The company is a client of the stockbroking division of the Meristem group.
- j. The company is a client of the investment banking division of the Meristem group.
- k. Meristem is the registrar of the company.
- The company owns more than 5% of the issued share capital of Meristem
- m. Meristem has other financial or other material interests in the company.

# **CONTACT INFORMATION**

**Brokerage and Retail Services** 

topeoludimu@meristemng.com (+234 905 569 0627) adaezeonyemachi@meristemng.com (+234 808 369 0213)

contact@meristemng.com

**Investment Banking/Corporate Finance** 

<u>rasakisalawu@meristemng.com</u> (+234 806 022 9889) <u>davidadu@meristemng.com</u> (+234 810 940 4836)

**Wealth Management** 

<u>funmilolaadekola-daramola@meristemng.com</u> (+234 803 355 0008) <u>crmwealth@meristemng.com</u> (+234 01 738 9948)

Registrars

<u>oluseyiowoturo@meristemregistrars.com</u> (+234 802 321 0561) <u>www.meristemregistrars.com</u> (+23401-280 9250)

**Trust Services** 

damilolahassan@meristemng.com (+234 803 613 9123)

trustees@meristemng.com

**Group Business Development** 

sulaimanadedokun@mersitemng.com (+234 803 301 3331)
ifeomaogalue@meristemng.com (+234 802 394 2967)
info@meristemng.com

**Investment Research** 

<u>praiseihansekhien@meristemng.com</u> (+234 817 007 1512) <u>research@meristemng.com</u>

Analyst(s)

jenniferaudu@meristemng.com (+234 805 296 4933)

**Client Services** 

<u>adefemitaiwo@meristemng.com</u> (+234 803 694 3034) <u>brandandcomms@meristemng.com</u> (+23401-280 9250)

Corporate websites: <a href="https://www.meristemng.com">www.meristemng.com</a> <a href="https://www.meristemng.com">www.meristemng.com</a> <a href="https://www.meristemng.com">www.meristemng.com</a> <a href="https://www.meristemng.com">www.meristemng.com</a>

Meristem Research can also be accessed on the following platforms:

Meristem Research Portal: research.meristemng.com

**Bloomberg**: MERI <GO>

Capital IQ: www.capitaliq.com

ISI Emerging Markets: www.securities.com/ch.html?pc=NG

Reuters: www.thomsonreuters.com

FactSet: www.factset.com